Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.
Erica D WarlickCelalettin UstunAstrid AndreescuAnthony F BonaguraAndrew BrunnerAbhinav B ChandraJames M ForanMark B JuckettTamila L Kindwall-KellerVirginia M KlimekDaniel F PeaseDavid P SteensmaBryce M WaldmanMary M HorowitzLinda J BurnsNandita KheraPublished in: Cancer (2021)
People who have advanced myelodysplastic syndromes (MDS) may live longer if they get a bone marrow transplant (BMT) instead of other therapies. However, only 15% of people with MDS actually get BMT. Experts say community physicians and transplant physicians should team up with insurance companies and patient advocacy groups to 1) spread this news about lifesaving advances in BMT, 2) ensure that everyone can afford health care, 3) provide emotional support for patients and families, 4) help patients and families get transportation and housing if they need to travel for transplant, and 5) improve care for people of under-represented racial and ethnic backgrounds.
Keyphrases
- healthcare
- end stage renal disease
- primary care
- bone marrow
- clinical trial
- newly diagnosed
- chronic kidney disease
- ejection fraction
- palliative care
- quality improvement
- peritoneal dialysis
- mesenchymal stem cells
- randomized controlled trial
- social media
- case report
- mental health
- patient reported outcomes
- health insurance
- study protocol
- long term care